BiotechTube

KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0%

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ocular Infections, Irritations and Inflammations

Conditions

Ocular Infections, Irritations and Inflammations

Trial Timeline

May 1, 2014 → Dec 1, 2014

NCT ID
NCT02163824

About KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0%

KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0% is a phase 3 stage product being developed by Kala Pharmaceuticals for Ocular Infections, Irritations and Inflammations. The current trial status is completed. This product is registered under clinical trial identifier NCT02163824. Target conditions include Ocular Infections, Irritations and Inflammations.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02163824Phase 3Completed

Competing Products

20 competing products in Ocular Infections, Irritations and Inflammations

See all competitors
ProductCompanyStageHype Score
lotilaner + VehicleTarsus PharmaceuticalsPhase 2
47
Mirabegron + PlaceboAstellas PharmaPhase 1
33
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ISV-303Sun PharmaceuticalPhase 3
77
ONO-9054 + LatanoprostOno PharmaceuticalPhase 2
52
ONO-9054 + PlaceboOno PharmaceuticalPhase 1
33
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
77
Tafluprost, timolol maleateSanten PharmaceuticalPre-clinical
23
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
77
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
52
dorzolamide hydrochloride (+) timolol maleateMerckApproved
85
INS115644 Ophthalmic Solution + Placebo + INS115644 Ophthalmic Solution + INS115644 Ophthalmic Solution + INS115644 Ophthalmic SolutionMerckPhase 1
33
SAD448NovartisPhase 1
33

Other Products from Kala Pharmaceuticals

loteprednol etabonate 0.25% ophthalmic suspensionApproved
77
KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BIDPhase 3
69
KPI-121 1% + Prednisolone acetatePhase 3
69
KPI-121 Ophthalmic Suspension + VehiclePhase 3
69
KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic SuspensionPhase 3
69